CLL

expert roundtables

by Jennifer R. Brown, MD, PhD, Jan A. Burger, MD, PhD, Anthony Mato, MD, MSCE

Minimal residual disease (MRD) negativity after chemoimmunotherapy is associated with improved progression-free and overall survival in patients wi......READ MORE

clinical study insights

by Jan A. Burger, MD, PhD

Clinical Study Title:Targeting B Cell Receptor Signalling in Cancer: Preclinical and Clinical AdvancesClinical Study Abstract:B cell receptor (BCR)......READ MORE

patient care perspectives

by Anthony Mato, MD, MSCE

Owing to the epidemiology of chronic lymphocytic leukemia (CLL), age-associated comorbidities are commonly present at the time of CLL treatment ini......READ MORE

clinical study insights

by Anthony Mato, MD, MSCE

Clinical Study Title:Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results From a Multicenter Study ......READ MORE

expert roundtables

by Jennifer R. Brown, MD, PhD, Jan A. Burger, MD, PhD, Anthony Mato, MD, MSCE

With the introduction of novel therapies for chronic lymphocytic leukemia (CLL), interest in the possibility of earlier treatment has led to the in......READ MORE